[{"address1": "10628 Science Center Drive", "address2": "Suite 250", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 900 2660", "website": "https://arcturusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.", "fullTimeEmployees": 180, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph E. Payne M.Sc.", "age": 51, "title": "Founder, President, CEO & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 906500, "exercisedValue": 0, "unexercisedValue": 5381721}, {"maxAge": 1, "name": "Dr. Padmanabh  Chivukula Ph.D.", "age": 44, "title": "Founder, Chief Scientific Officer, COO & Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 687500, "exercisedValue": 0, "unexercisedValue": 4401638}, {"maxAge": 1, "name": "Mr. Andrew H. Sassine MBA", "age": 59, "title": "CFO & Director", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 687500, "exercisedValue": 0, "unexercisedValue": 5663780}, {"maxAge": 1, "name": "Mr. Lance  Kurata", "title": "Chief Legal Officer", "fiscalYear": 2023, "totalPay": 600000, "exercisedValue": 0, "unexercisedValue": 456563}, {"maxAge": 1, "name": "Ms. Neda  Safarzadeh", "title": "Vice President and Head of IR/PR & Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Natash O. Bowman", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin T. Skol", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Juergen  Froehlich FCPh, M.D., MBA", "age": 67, "title": "Chief Medical Officer", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Igor  Smolenov M.D., Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Roberta  Duncan", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 6, "overallRisk": 9, "governanceEpochDate": 1716940800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 36.72, "open": 37.0, "dayLow": 36.02, "dayHigh": 38.51, "regularMarketPreviousClose": 36.72, "regularMarketOpen": 37.0, "regularMarketDayLow": 36.02, "regularMarketDayHigh": 38.51, "beta": 2.654, "forwardPE": -37.72549, "volume": 520177, "regularMarketVolume": 520177, "averageVolume": 520065, "averageVolume10days": 496330, "averageDailyVolume10Day": 496330, "bid": 38.39, "ask": 38.59, "bidSize": 200, "askSize": 200, "marketCap": 1036335680, "fiftyTwoWeekLow": 17.52, "fiftyTwoWeekHigh": 43.81, "priceToSalesTrailing12Months": 8.322244, "fiftyDayAverage": 30.2314, "twoHundredDayAverage": 29.5471, "currency": "USD", "enterpriseValue": 779862656, "profitMargins": -0.86164004, "floatShares": 24575561, "sharesOutstanding": 26931800, "sharesShort": 4128904, "sharesShortPriorMonth": 4613132, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1533, "heldPercentInsiders": 0.08743, "heldPercentInstitutions": 0.98837, "shortRatio": 8.39, "shortPercentOfFloat": 0.24110001, "impliedSharesOutstanding": 26931800, "bookValue": 9.807, "priceToBook": 3.9237278, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -107296000, "trailingEps": -4.03, "forwardEps": -1.02, "lastSplitFactor": "1:7", "lastSplitDate": 1510790400, "enterpriseToRevenue": 6.263, "enterpriseToEbitda": -6.538, "52WeekChange": 0.43154764, "SandP52WeekChange": 0.22256601, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ARCT", "underlyingSymbol": "ARCT", "shortName": "Arcturus Therapeutics Holdings ", "longName": "Arcturus Therapeutics Holdings Inc.", "firstTradeDateEpochUtc": 1369229400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cb9a2721-c1b9-3b25-9cc5-ea57e34e4857", "messageBoardId": "finmb_235062181", "gmtOffSetMilliseconds": -14400000, "currentPrice": 38.48, "targetHighPrice": 140.0, "targetLowPrice": 48.0, "targetMeanPrice": 74.57, "targetMedianPrice": 60.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 288396000, "totalCashPerShare": 10.708, "ebitda": -119289000, "totalDebt": 31922000, "quickRatio": 2.733, "currentRatio": 3.256, "totalRevenue": 124526000, "debtToEquity": 12.093, "revenuePerShare": 4.662, "returnOnAssets": -0.17221001, "returnOnEquity": -0.36174, "freeCashflow": -4989500, "operatingCashflow": 12215000, "revenueGrowth": -0.527, "grossMargins": 0.87187, "ebitdaMargins": -0.95794, "operatingMargins": -0.77902, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-31"}]